Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy

AXL overexpression is a common resistance mechanism to anticancer therapies, including the resistance to BYL719 (Alpelisib) — the p110α isoform specific inhibitor of phosphoinositide 3-kinase (PI3K) — in esophagus squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC). Howe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Badarni, Mai, Prasad, Manu, Balaban, Noa, Zorea, Jonathan, Yegodayev, Ksenia M., Joshua, Ben-Zion, Dinur, Anat Bahat, Grénman, Reidar, Rotblat, Barak, Cohen, Limor, Elkabets, Moshe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538319/
https://ncbi.nlm.nih.gov/pubmed/30860495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados